fluconazole has been researched along with Vaginal Discharge in 5 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
Vaginal Discharge: A common gynecologic disorder characterized by an abnormal, nonbloody discharge from the genital tract.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The high prevalence of Candida infection, especially those due to non-albicans Candida species that are resistant to fluconazole, is a great concern in our setting and may lead to poor treatment outcomes." | 8.12 | Importance of Candida infection and fluconazole resistance in women with vaginal discharge syndrome in Namibia. ( Dunaiski, CM; Jung, H; Kock, MM; Peters, RPH, 2022) |
| "A randomized controlled effectiveness trial compared single-dose tinidazole plus fluconazole (TF) with treatment for 7 days with metronidazole plus 3 days of treatment with vaginal clotrimazole (MC) among 1570 women presenting with vaginal discharge at primary health care institutions in Ghana, Guinea, Mali and Togo." | 5.12 | The syndromic management of vaginal discharge using single-dose treatments: a randomized controlled trial in West Africa. ( Agyarko-Poku, T; Asamoah-Adu, C; Deslandes, S; Diakité, S; Frost, E; Khonde, N; Labbé, AC; Pépin, J; Sobela, F; Sylla, M, 2006) |
| "The high prevalence of Candida infection, especially those due to non-albicans Candida species that are resistant to fluconazole, is a great concern in our setting and may lead to poor treatment outcomes." | 4.12 | Importance of Candida infection and fluconazole resistance in women with vaginal discharge syndrome in Namibia. ( Dunaiski, CM; Jung, H; Kock, MM; Peters, RPH, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dunaiski, CM | 1 |
| Kock, MM | 1 |
| Jung, H | 1 |
| Peters, RPH | 1 |
| Ghaddar, N | 1 |
| Anastasiadis, E | 1 |
| Halimeh, R | 1 |
| Ghaddar, A | 1 |
| Dhar, R | 1 |
| AlFouzan, W | 1 |
| Yusef, H | 1 |
| El Chaar, M | 1 |
| Sim, M | 1 |
| Logan, S | 1 |
| Goh, LH | 1 |
| Ressel, GW | 1 |
| Pépin, J | 1 |
| Sobela, F | 1 |
| Khonde, N | 1 |
| Agyarko-Poku, T | 1 |
| Diakité, S | 1 |
| Deslandes, S | 1 |
| Labbé, AC | 1 |
| Sylla, M | 1 |
| Asamoah-Adu, C | 1 |
| Frost, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised Controlled Trial of Single Dose Tinidazole+Fluconazole Versus Longer Courses of Metronidazole+Clotrimazole in the Management of West African Women With Vaginal Discharge[NCT00313131] | Phase 3 | 1,524 participants | Interventional | 2004-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for fluconazole and Vaginal Discharge
| Article | Year |
|---|---|
The syndromic management of vaginal discharge using single-dose treatments: a randomized controlled trial in West Africa.
Topics: Adolescent; Adult; Africa, Western; Animals; Anti-Infective Agents; Antifungal Agents; Antitrichomon | 2006 |
4 other studies available for fluconazole and Vaginal Discharge
| Article | Year |
|---|---|
Importance of Candida infection and fluconazole resistance in women with vaginal discharge syndrome in Namibia.
Topics: Antifungal Agents; Candida; Candidiasis; Cross-Sectional Studies; Female; Fluconazole; Humans; Male; | 2022 |
Prevalence and antifungal susceptibility of Candida albicans causing vaginal discharge among pregnant women in Lebanon.
Topics: Adult; Amphotericin B; Antifungal Agents; Candida albicans; Candida glabrata; Candidiasis, Vulvovagi | 2020 |
Vaginal discharge: evaluation and management in primary care.
Topics: Anti-Infective Agents; Antifungal Agents; Female; Fluconazole; Humans; Metronidazole; Primary Health | 2020 |
CDC releases 2002 guidelines for treating STDs: Part I. Diseases characterized by vaginal discharge and PID.
Topics: Anti-Infective Agents; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; Metronidazole; Pelvic | 2002 |